Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tenofovir DF/Atazanavir + Ritonavir in HIV Patients With Multiple Treatment Failures
NCT00122577Phase 2Terminated
- Sponsor
- ANRS
- Start
- Mar 2002
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of atazanavir and tenofovir in human immunodeficiency virus infection (HIV) (2 arms), sponsored by ANRS. Primary endpoints: Change in plasma HIV RNA level at 26 weeks and Percentage of patients with undetectable HIV-RNA in plasma at 26 weeks. Started Mar 2002; status: terminated.
02
Drugs
atazanavirtenofovir
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT00122577.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00122577.